Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations
Abstract The human epidermal growth factor receptor 2 (HER2) alterations are significant genetic alterations in non-small cell lung cancer (NSCLC), encompassing mutations, amplifications, and protein overexpression. Despite the substantial progress of anti-HER2 targeted therapies in breast and gastr...
Saved in:
| Main Authors: | Jiang Liu, Jianhua Liu, Jianhe Yu, Qun Ren, Yin Cai, Dadong Chen, Chuanjun Song |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Journal of Translational Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12967-025-06589-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HER2-Low Breast Cancer—Current Knowledge and Future Directions
by: Abeer M. Shaaban, et al.
Published: (2025-04-01) -
Monitoring and management of adverse effects associated with trastuzumab deruxtecan: a UAE-specific consensus
by: Emad Dawoud, et al.
Published: (2025-01-01) -
Development of a bispecific antibody–drug conjugate targeting EpCAM and CLDN3 for the treatment of multiple solid tumors
by: Meiying Luo, et al.
Published: (2025-03-01) -
Efficacy and safety of trastuzumab deruxtecan in gastrointestinal malignancies: a systemic review and meta-analysis
by: Ali Hussain, et al.
Published: (2025-04-01) -
Progress of Research on Advanced Non-Small Cell Lung Cancer with HER-2 Mutation
by: Liang ZHANG, et al.
Published: (2025-02-01)